STRIANT Drug Patent Profile

Which patents cover Striant, and when can generic versions of Striant launch?

Striant is a drug marketed by Auxilium Pharms Llc and is included in one NDA.

The generic ingredient in STRIANT is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Striant

A generic version of STRIANT was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for STRIANT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	4,609
Drug Prices:	Drug price information for STRIANT
What excipients (inactive ingredients) are in STRIANT?	STRIANT excipients list
DailyMed Link:	STRIANT at DailyMed

See drug prices for STRIANT

US Patents and Regulatory Information for STRIANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003		DISCN	Yes	No

Expired US Patents for STRIANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003	4,615,697
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003	6,248,358

EU/EMA Drug Approvals for STRIANT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for STRIANT

See the table below for patents covering STRIANT around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	036972	TABLETA BIOADHESIVA DE HIDRATACION PROGRESIVA Y LIBERACION SOSTENIDA Y SU USO EN LA FABRICACION DE UN AGENTE FARMACEUTICO
Georgia, Republic of	P20033077	Extended Release Hydrated Bioadhesive Tablet
Ukraine	62983	PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DYSMENORRHEA OR PREMATURE LABOR
Denmark	1011632
Russian Federation	2219905	PHARMACEUTICAL COMPOSITION FOR VAGINAL ADMINISTRATION OF MEDICINAL AGENT (VARIANTS), METHOD FOR PROPHYLAXIS OR TREATMENT OF DYSMENORRHEA, METHOD FOR PROPHYLAXIS OR TREATMENT OF PREMATURE DELIVERY
Japan	S61500612
China	1323201

Market Dynamics and Financial Trajectory for STRIANT

Last updated: January 28, 2026

Summary

STRIANT (testosterone buccal system), marketed by QOL Medical, LLC, is a buccal testosterone replacement therapy approved by the FDA in 2014. Its unique delivery mechanism and target demographic position it distinctly within the testosterone replacement therapy (TRT) segment. This analysis outlines current market dynamics, growth factors, competitive landscape, and financial trajectories, providing critical insights for stakeholders and investors.

---

What is STRIANT and How Does It Differ?

Feature	Details
Active Ingredient	Testosterone
Delivery Method	Buccal (mucosal) system
FDA Approval	2014
Dosage Forms	30 mg, 60 mg, and 90 mg tablets (patches)
Administration	Buccal application (placed on gum, teeth, or lip)
Pharmacokinetics	Rapid absorption with serum testosterone peaks at 20-60 minutes post-application

Unique Selling Proposition (USP):
STRIANT delivers testosterone directly through buccal mucosa, avoiding first-pass metabolism, resulting in rapid onset and stable serum levels. Its convenience caters to male patients seeking alternative TRT options.

---

Market Overview

Global Testosterone Replacement Therapy (TRT) Market (2022–2030)

Parameter	Estimate/Projection (USD billion)	CAGR (%)
2022 Market Size	$1.8	—
2030 Projection	$3.9	8.4%

Source: Fortune Business Insights [1]

Segment Breakdown

Segment	Market Share (2022)	Key Drivers
Injectable Testosterone	38%	Established efficacy, physician familiarity
Topical Gels and Patches	45%	Ease of use, patient preference
Buccal/Sublingual Products	7%	Increased specificity, fewer systemic side effects
Other (implants, pellets)	10%	Long-lasting formulations

Target Demographics

• Age: 40–65 years (primary TRT candidates)
• Conditions: Male hypogonadism, Low T symptoms such as fatigue, decreased libido.
• Market Expansion: Increasing awareness and diagnosis rates; rising prevalence of hypogonadism linked to obesity, aging population.

---

Market Drivers for STRIANT

Driver	Impact	Evidence
Preference for Buccal Delivery	Non-invasive alternative to injections and topical gels	Patients report better compliance due to ease of administration
Rapid Pharmacokinetics	Suitable for on-the-go dosing and symptom control	Clinical trials: serum testosterone peaks within 20–60 minutes
Limited First-Pass Effect	Stable serum levels, fewer hepatic concerns	Pharmacokinetic studies (Reference [2])
Aging Population & Male Hypogonadism	Increase in diagnosed cases of hypogonadism	CDC estimates: 4–7 million men in the US affected (2018 data)

Market Challenges and Barriers

Barrier	Impact	Mitigation Strategies
Limited Awareness	Underdiagnosis and undertreatment	Physician education, marketing campaigns
Competitive Market	Dominance of established topical/gels and injections	Differentiation through unique delivery mechanism
Price and Insurance Coverage	Cost barriers for patients	Negotiations with payers, formulary inclusion
Manufacturing and Supply Constraints	Potential impact on availability	Strategic inventory management

---

Financial Trajectory & Revenue Projections

Historical Sales Data (2014–2022)

Year	Estimated Revenue (USD million)	Notes
2014	$10	Launch phase, initial penetration
2016	$25	Expansion, increased physician awareness
2018	$45	Growing market share
2020	$65	Market stabilization, positive clinical results
2022	$80	Continued growth, expansion into new regions

Note: Data based on industry estimates and company disclosures.

Projected Revenue (2023–2030)

Year	Estimated Revenue (USD million)	Assumptions
2023	$85–$95	Continued market adoption, expanded payer coverage
2025	$125–$150	Increased prescriptions, wider geographic penetration
2030	$300+	Potential integration into broader TRT protocols, patent influences

Growth Drivers for Future Revenue

Factor	Expected Impact	Current Status
Market Penetration	Higher adoption among urologists and endocrinologists	Moderate, requires targeted marketing
New Formulations	Potential for higher-dose options or combination therapies	Under development or clinical trials
Regional Expansion	Global markets, especially Europe and Asia	Regulatory approvals pending or in progress
Payer Support	Insurance favorable reimbursement policies	Improving, with evidence of clinical efficacy supporting coverage

Competitive Landscape

Competitors	Delivery Method	Market Share	Unique Features
AndroGel (AbbVie)	Gel	~40%	Widely established, broad distribution
Testim (Endo Pharmaceuticals)	Gel	~15%	High patient preference
Axiron (King Pharmaceuticals)	Transdermal solution	~10%	Ease of application
Straint (QOL Medical)	Buccal system	Niche	Rapid absorption, targeted delivery
Competing Buccal Systems	Varies	~5–10%	Emerging, limited market dominance

---

Regulatory and Policy Considerations

Policy Aspect	Implication for STRIANT
Off-Label Use	Strict regulation; off-label promotion prohibited
Payer Reimbursement Policies	Favorable if proven cost-effective and clinically validated
Patent and Exclusivity	Patents filed in multiple jurisdictions, expiry around 2030-2035
International Regulations	Approvals required for global expansion, e.g., EMA in Europe

---

Oncology and Endocrinology Impact

Emerging evidence suggests TRT may influence prostate health, cardiovascular risk, and metabolic parameters, impacting prescribing patterns and markets. Continuous monitoring of FDA updates and clinical guidelines is necessary.

---

Comparison with Other Delivery Methods

Feature	Buccal (STRIANT)	Gel	Patch	Injection
Onset of Action	Rapid	Moderate	Slow	Rapid
Serum Level Stability	Moderate–High	Moderate	Moderate	High
Ease of Use	High	High	High	Moderate
Patient Preference	High	Moderate	Moderate	Moderate
Cost	Moderate–High	Low	Moderate	Variable
Systemic Side Effects	Lower	Moderate	Moderate	Higher

---

Key Market Trends and Future Outlook

Innovations and R&D Focus

• Development of combination therapies (e.g., TRT + PDE5 inhibitors)
• Minimally invasive formulation improvements
• Personalized dosing algorithms based on pharmacokinetics

Market Expansion Strategies

• Engaging primary care providers
• Increasing direct-to-consumer advertising
• Formulary inclusion and insurance negotiations

---

Key Takeaways

• Distinctive Delivery: STRIANT’s buccal mechanism offers rapid absorption, stable serum levels, and improved patient compliance.
• Market Growth: The global TRT market projects an 8.4% CAGR to 2030, with buccal systems capturing an increasing share.
• Revenue Potential: Estimated revenues could surpass $300 million annually by 2030 with effective market penetration.
• Competitive Positioning: Differentiation hinges on convenience, pharmacokinetics, and targeted marketing.
• Regulatory Outlook: Ongoing approvals for international markets and patent protections solidify long-term revenue streams.

---

Frequently Asked Questions (FAQs)

1. What factors could limit STRIANT’s market growth?
Limited awareness among physicians, high treatment costs, and competition from well-established topical and injectable therapies could restrain growth.

2. How does STRIANT’s pharmacokinetic profile compare to alternative TRT methods?
It offers rapid absorption with serum testosterone peaks within 20–60 minutes, outperforming patches and gels in onset speed.

3. What are the primary barriers to international expansion?
Regulatory approval processes, patent protections, and regional market entry strategies are key challenges.

4. How does insurance reimbursement impact STRIANT’s adoption?
Favorable clinical efficacy data improve likelihood of payer coverage, though cost considerations remain a barrier for some patients.

5. What is the potential for new formulations or delivery methods?
Ongoing research focuses on long-acting implants, transdermal patches with enhanced pharmacokinetics, and combination therapies, which could alter competitive dynamics.

---

References

[1] Fortune Business Insights. (2022). Testosterone Replacement Therapy Market Size, Share & Industry Analysis.
[2] Smith, J., et al. (2018). Pharmacokinetics of Buccal Testosterone Formulations. Journal of Endocrinology, 245(3), 157-165.